Help create more awareness! Please share this article…
A hold that was placed on a remarkable breakthrough cancer treatment invented by Dr. Stanislaw Burzynski has finally been lifted by the FDA.
It should have been news that sent shock-waves throughout the industry, so large that even the establishment’s media could not ignore them. Spilling out onto every radio and news station in the country, if not the world.
But once again, another huge victory against the medical establishment for a Houston-based doctor that has been using a breakthrough technology he invented to literally cure cancer on many occasions, who for all-intents-and-purposes should be a household name by now and an easy Nobel Prize winner, is instead nowhere to be found, as if it never even happened.
That’s because Dr. Stanislaw Burzynski and his cancer-curing discovery, “Antineoplastons,” including a remarkable, relatively new gene-targeted therapy, threatens the very way of life to which the Western medical cancer and sick-care industry has become accustom. Raking in billions a year off of the desperate backs of people suffering from debilitating and deadly diseases in which the Western medical industry does not truly want to find a cure.
Despite a track record dwarfing that of conventional cancer treatments, including outright curing some forms that, until now, were previously thought of as “incurable,” the government and the medical establishment has been fighting tooth-and-nail to prevent public knowledge of this technology from crossing the Rubicon and becoming too widely known to stop, without real public backlash. Well, now, it may soon be too late for that.
That’s because only days ago, the Burzynski Research Institute, Inc. (BRI) released a statement to the media explaining that the U.S. Food and Drug Administration (FDA) has finally ended their latest attempt to stifle his lifetime’s work and a breakthrough that will likely revolutionize the way cancer is viewed and treated. Surprisingly lifting a two-year “partial” clinical hold on an Investigational New Drug (IND) application for Antineoplastons A10/AS2-1 Injections and finally clearing the way for long-awaited Phase 3 trials for newly-diagnosed cancer patients. Initially for a specific form of cancer, known as Diffuse Intrinsic Brainstem Glioma.
Essential Stories: He Holds The Patent That Could DESTROY Monsanto And Change The World!
Considering the already proven success rates prior to the government hold, for both Glioma during Phase 2 trials and many other forms of cancer individually, most of the naysayers, critics and skeptics are going to have a tough time pretending the opposite. Giving a much needed booster to an industry that has been suffering from almost total corruption and manipulation of the Hippocratic Oath for a very, very long time.
Although it would be more of a shock if the medical establishment actually stopped trying to put an end to what could end up helping the public at-large become aware of much more than decades of official suppression of life-saving treatments and cures, the FDA’s surprising decision now makes way for an extremely important step in the progression of Antineoplastons’ use for various forms of brain tumors and many, if not most other types of cancers in the US.